

Clinical trials of beta-blockers for heart failure in all type of heart failure

TrialResults-center www.trialresultscenter.org

1 beta-blockers

Trial	Treatments	Patients	Trials design and methods
bisoprolol vs placebo			
CIBIS , 1994 n=320/321 follow-up: 1.9 years (range 4-44 mo)	bisoprolol 5mg/d versus placebo	stable chronic idiopathic dilated cardiomyopathy heart failure NYHA 3-4, EF<40%	Parallel groups Double blind 9 european countries
CIBIS II , 1999 n=1327/1320 follow-up: 1.3 years	Bisoprolol target dose 10mg/daily versus control	chronic herat failure, ejection fraction<=35% , NYHA 3-4	Parallel groups Double blind western and eastern europe
bucindolol vs placebo			
Pollock , 1990 n=12/7 follow-up: 3 months	bucindolol target dose 100mg twice daily versus placebo	Patientst with stable, chronic heart failure with a dilated cardiomyopathy due to ischemic or isopathic causes	Parallel groups Double blind US
Woodley , 1991 n=29/29 follow-up: 3 mo	bucindolol versus placebo	NYHA 2-3, IDC/CAD	
Bristow , 1994 n=105/34 follow-up: 3 mo	bucindolol versus placebo	NYHA 2-3, IDC	
BEST , 2001 [NCT00000560] n=1354/1354 follow-up: 2 years	bucindolol titrated to 50mg txice daily versus placebo	patients with heart failure NYHA class III or IV and a left ventricular ejection fraction of 35 percent or lower	Parallel groups Double blind US, Canada
carvedilol vs placebo			
ANZ-HeFT , 1997 n=207/208 follow-up: 19 mo (range 18-24 mo)	carvedilol target dose 25mg twice daily versus placebo	chronic stable heart failure, NYHA 1-3	Parallel groups Double blind Australia & New Zealand
Parker , 1996 n=696/398 follow-up: 6.5 mo (1 day - 15.1 mo)	carvediloltarget dose 25 mg twice daily versus placebo	patients with heart failure and ejection fraction<0.35	Parallel groups Double blind US
Metra , 1994 n=20/20 follow-up: 4 mo	carvedilol versus placebo	NYHA 2-3, IDC	

continued...

Trial	Treatments	Patients	Trials design and methods
Olsen , 1995 n=36/23 follow-up: 4 mo	carvedilol versus placebo	NYHA 2-4, IDC/CAD	
Krum , 1995 n=33/16 follow-up: 3.5 mo	carvedilol 25 mg twice daily during 14 weeks versus placebo	Patients with advanced heart failure(NYHA 3-4), EF <=0.35	
Bristow (MOCHA) , 1996 n=261/84 follow-up: 6.5-8 mo	carvedilol versus placebo	NYHA 2-4, IDC/CAD	Parallel groups Double blind
Colucci , 1996 n=232/134 follow-up: 213 days (0.6 years)	carvedilol versus placebo	mild symptomatic heart failure; ejection fraction<=0.35; 6-minute walk test of 450-550m; on optimal standard therapy including ACE inhibitors	Parallel groups Double blind US
Cohn , 1997 n=70/35 follow-up: <8 mo	carvedilol versus placebo	NYHA 3-4, IDC/CAD	
CAPRICORN , 2001 n=975/984 follow-up: 1.3 years	carvedilol target dose 25mg twice daily versus placebo	proven acute myocardial infarction and a left-ventricular ejection fraction of <=40%	Parallel groups Double blind 17 countries
COPERNICUS , 2002 n=1156/1133 follow-up: 10.4 months	carvedilol traget dose of 25 mg twice daily versus placebo	patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded)	Parallel groups Double blind worldwide (21 countries)
metoprolol vs placebo			
Engelmeier , 1985 n=9/16 follow-up: 12 mo	metoprolol versus placebo	NYHA 2-4, IDC	
MDC (Waagstein) , 1993 n=194/189 follow-up: 18 months	metoprolol target dose 100-150 mg daily (dose divided into two or three per day) versus placebo	patient with heart failure due to idiopathic dilated cardiomyopathy (NYHA 1-3) and EF<40%	Parallel groups Double blind Europe, North America
Fisher , 1994 n=25/25 follow-up: 6 mo	metoprolol versus placebo	NYHA 3-4, CAD	
Eichhorn , 1994 n=15/9 follow-up: 3 mo	metoprolol versus placebo	NYHA 2-3, IDC	
MERIT-HF , 1999 n=1990/2001 follow-up: 1 y	metoprolol CR/XL at target dose of 200 mg once daily versus placebo	patients with chronic heart failure in New York Heart Association (NYHA) functional class IIIIV and with ejection fraction of 040 or less, stabilised with optimum standard therapy	Parallel groups Double blind USA and Europe

continued...

Trial	Treatments	Patients	Trials design and methods
RESOLVD , 2000 n=214/212 follow-up: 6 mo	metoprolol CR 200 mg/d versus placebo	CHF of mixed causes, patients with symptomatic CHF(NYHA II to IV), a 6-minute walk distance of <500 m, and an LV ejection fraction (EF) of<40%	Parallel groups Double aveugle
Nebivolol vs placebo			
Lechat , 1991 n=6/6 follow-up: 1.5 month	nebivolol 5mg/d versus placebo	NYHA 3-4	Parallel groups Double aveugle France
Wisnibaugh , 1993 n=11/13 follow-up: 3 mo	nebivolol versus placebo	patients with dilated idiopathic or ischemic cardiomyopathy (ejection fraction 0.15 to 0.40) in stable NYHA class II or III	Parallel groups double blind
SENIORS , 2005 n=1067/1061 follow-up: 21 months	nebivolol (titrated from 1.25 mg once daily to 10 mg once daily) versus placebo	patients aged 70 years with a history of heart failure (hospital admission for heart failure within the previous year or known ejection fraction 35%),	Parallel groups Double blind Europe
carvedilol vs enalapril			
CARMEN (carvedilol alone) , 2004 n=191/190 follow-up: 18 months	carvedilol (target 25 mg bid) versus enalapril (target 10 mg bid)	patients with mild heart failure	ND
carvedilol+enalapril vs enalapril			
CARMEN (carvedilol+enalapril) , 2004 ongoing n=191/190 follow-up: 18 months	carvedilol (target 25 mg bid) + enalapril (target 10 mg bid) versus enalapril (target 10 mg bid)	patients with mild heart failure	NA
carvedilol vs metoprolol			
COMET , 2003 n=1511/1518 follow-up: 4.83 years	carvedilol (target dose 25 mg twice daily) versus metoprolol tartrate target dose 50 mg twice daily	chronic heart failure (NYHA IIIIV) with a previous admission for a cardiovascular reason and ejection fraction of less than 035, and have been treated optimally with diuretics and angiotensinverting enzyme inhibitors unless not tolerated.	Parallel groups Double blind 15 European countries

References

CIBIS, 1994:

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. *Circulation* 1994;90:1765-73 [7923660]

, A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. *Circulation* 1994; 90:1765-73 [7923660]

Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation* 1997 Oct 7;96:2197-205 [9337190]

CIBIS II, 1999:

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353:9-13 [[10023943](#)]

Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. *Circulation* 2001 Mar 13;103:1428-33 [[11245648](#)]

Pollock, 1990:

Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML, Usefulness of bucindolol in congestive heart failure. *Am J Cardiol* 1990; 66:603-7 [[1975473](#)]

Woodley, 1991:

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, et al, Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 1991; 84:2426-41 [[1683602](#)]

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, et al, Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 1991; 84:2426-41 [[1683602](#)]

Bristow, 1994:

Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al, Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. *Circulation* 1994; 89:1632-42 [[7908610](#)]

BEST, 2001:

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med* 2001 May 31;344:1659-67 [[11386264](#)]

ANZ-HeFT, 1997:

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. *Lancet* 1997;349:375-80 [[9033462](#)]

, Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. *Circulation* 1995; 92:212-8 [[7600653](#)]

, Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. *Lancet* 1997; 349:375-80 [[9033462](#)]

Parker, 1996:

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. *Circulation* 1996; 94:2793-9 [[8941104](#)]

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 1996; 334:1349-55 [[8614419](#)]

Metra, 1994:

Metra M, Nardi M, Giubbini R, Dei Cas L, Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 1994; 24:1678-87 [[7963115](#)]

Olsen, 1995:

Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR, Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. *J Am Coll Cardiol* 1995; 25:1225-31 [[7722114](#)]

Krum, 1995:

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al, Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. *Circulation* 1995; 92:1499-506 [[7664433](#)]

Bristow (MOCHA), 1996:

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. *Circulation* 1996; 94:2807-16 [[8941106](#)]

Colucci, 1996:

Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. *Circulation* 1996; 94:2800-6 [8941105]

Cohn, 1997:

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA, Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. *J Card Fail* 1997; 3:173-9 [9330125]

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. *J Card Fail* 1997 Sep;3:173-9 [9330125]

CAPRICORN, 2001:

Dargie HJ Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001 May 5;357:1385-90 [11356434]

COPERNICUS, 2002:

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002 Oct 22;106:2194-9 [12390947]

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001 May 31;344:1651-8 [11386263]

Engelmeier, 1985:

Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM, Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. *Circulation* 1985; 72:536-46 [3893793]

MDC (Waagstein), 1993:

Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet* 1993;342:1441-6 [7902479]

Fisher, 1994:

Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP, Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. *J Am Coll Cardiol* 1994; 23:943-50 [8106700]

Eichhorn, 1994:

Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR, Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol* 1994; 24:1310-20 [7930255]

MERIT-HF, 1999:

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) *Lancet* 1999;353:2001-7 [10376614]

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjeksus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Go Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 2000; 283:1295-302 [10714728]

RESOLVD, 2000:

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. *Circulation* 2000 Feb 1;101:378-84 [10653828]

Lechat, 1991:

Drug Invest 1991;3:69-81 [0]

Wisnibaugh, 1993:

Wisnibaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P, Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. *J Am Coll Cardiol* 1993; 21:1094-100 [[8096228](#)]

SENIORS, 2005:

Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005 Feb;26:215-25 [[15642700](#)]

CARMEN (carvedilol alone), 2004:

Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Scherhag A, Lutiger B, Ryden L The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). *Cardiovasc Drugs Ther* 2004 Jan;18:57-66 [[15115904](#)]

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Ryden L, Scherhag A, Soler-Soler J, Remme WJ Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). *Eur J Heart Fail* 2004 Jun;6:467-75 [[15182773](#)]

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydn L, Scherhag A, Soler-Soler J, Remme WJ Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). *Eur J Heart Fail* 2004 Jun;6:467-75 [[15182773](#)]

CARMEN (carvedilol+enalapril), 2004:

Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Scherhag A, Lutiger B, Rydn L The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). *Cardiovasc Drugs Ther* 2004 Jan;18:57-66 [[15115904](#)]

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydn L, Scherhag A, Soler-Soler J, Remme WJ Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). *Eur J Heart Fail* 2004 Jun;6:467-75 [[15182773](#)]

Remme WJ The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)—rationale and design. *Cardiovasc Drugs Ther* 2001 Jan;15:69-77 [[11504166](#)]

COMET, 2003:

Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003 Jul 5;362:7-13 [[12853193](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.